Key Highlights

  • Liquidity of USD 117.5 million, counting marketable securities, sat against a USD 280.7 million accumulated Deficit as of September 30, 2026.
  • Over 700 hospitals had adopted the Ceribell System by September 30, 2026, versus roughly 6,000 United States acute care facilities that the company believes could use it.
  • Three FDA clearances landed between December 2025 and September 2026, spanning delirium monitoring, two neurology algorithms, a new hardware generation and EEG trend software.
  • Management expects its cash to last at least a year and sees more than 3 million acute care patients annually as candidates for EEG monitoring.

Cash Holds Steady While the Hospital Footprint Expands

Ceribell (NASDAQ:CBLL) lodged its quarterly filing on November 3, 2026, for the period ending September 30. The medical technology Business sells a point-of-care electroencephalogram platform: disposable headbands connect to a pocket-sized recorder, and AI algorithms flag seizures and delirium in acute care settings. Staff can learn the device after roughly an hour of Training and apply it within minutes, while neurologists review recordings from a distance. The filing extract lacked quarterly Revenue and net loss figures, so this article concentrates on cash, adoption and regulatory progress. Cash and marketable securities came to USD 117.5 million, and more than 700 hospitals, ranging from large academic centers to small community sites, have adopted the system. Its Clarity product earned the first FDA clearance for diagnosing electrographic status epilepticus in May 2023.

FDA Clearances Broaden the Product Line and Revenue Mix

Three FDA 510(k) clearances followed: the Delirium Monitor System in December 2025, two neurology algorithms plus a next-generation hardware platform in June 2026, and quantitative EEG trending software in September 2026. Income arrives from two streams. Single-use Wearables generate revenue when control passes to the customer, while monthly subscriptions covering recorders, software and the portal are recognized across the contract term. Volume therefore depends on active accounts and Wearable usage, and the filing observes that intensive care patient counts tend to dip in summer, a Factor for the third quarter. Territory Managers pursue new accounts, while Clinical Account Managers try to deepen use in hospitals already on board, since clinicians do not necessarily apply the system to every eligible patient.

Operating Losses, Tariff Exposure and a Possible Capital Raise

The company anticipates continued operating losses as it scales, and it cautions that its 12-month cash view depends on assumptions that could prove mistaken. Should Operating Cash Flow fall short or spending run higher, it may need outside capital. Headbands are assembled by contract manufacturers in China and Vietnam, then inspected and labeled in Sunnyvale, California, and tariffs and shipping are included in cost of revenue. Major Wearable components have two sources of supply, and the company plans to enlarge its direct sales force. Commercial efforts concentrate on the United States, although the company holds a CE Mark for Europe. No peer comparison appeared in the material reviewed.

Where Things Stand

On its own estimate, Ceribell (NASDAQ:CBLL) has at least 12 months of runway, though the cushion is not quantified and the company warns it could burn cash faster. Against USD 117.5 million in cash and securities sits an accumulated deficit of USD 280.7 million, while more than 700 hospitals and a run of clearances broaden the offering. Without quarterly revenue or loss data in the extract, the Burn Rate cannot be measured here. Watch the complete financial statements, utilization growth inside existing hospitals and any capital raise.